Stock News

Alps Advisors Lifted By $2.90 Million Its Oge Energy (OGE) Stake; Dicerna Pharmaceuticals (DRNA) Sellers Increased By 23.45% Their Shorts

Dicerna Pharmaceuticals Incorporated (NASDAQ:DRNA) had an increase of 23.45% in short interest. DRNA’s SI was 458,500 shares in January as released by FINRA. Its up 23.45% from 371,400 shares previously. With 240,700 avg volume, 2 days are for Dicerna Pharmaceuticals Incorporated (NASDAQ:DRNA)’s short sellers to cover DRNA’s short positions. The SI to Dicerna Pharmaceuticals Incorporated’s float is 3.66%. The stock decreased 5.81% or $0.54 during the last trading session, reaching $8.76. About 702,644 shares traded or 144.31% up from the average. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has declined 5.22% since January 6, 2017 and is downtrending. It has underperformed by 21.92% the S&P500.

Alps Advisors Inc increased Oge Energy Corp (OGE) stake by 81.3% reported in 2017Q3 SEC filing. Alps Advisors Inc acquired 80,497 shares as Oge Energy Corp (OGE)’s stock declined 1.16%. The Alps Advisors Inc holds 179,509 shares with $6.47 million value, up from 99,012 last quarter. Oge Energy Corp now has $6.49 billion valuation. The stock decreased 0.31% or $0.1 during the last trading session, reaching $32.5. About 1.37 million shares traded or 28.17% up from the average. OGE Energy Corp. (NYSE:OGE) has risen 12.79% since January 6, 2017 and is uptrending. It has underperformed by 3.91% the S&P500.

Among 5 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Dicerna Pharmaceuticals had 17 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Hold” rating by Chardan Capital Markets given on Friday, August 11. The rating was reinitiated by Leerink Swann with “Mkt Perform” on Tuesday, January 31. The firm earned “Buy” rating on Friday, August 11 by H.C. Wainwright. The rating was maintained by Stifel Nicolaus on Thursday, June 30 with “Buy”. The company was maintained on Thursday, November 2 by Stifel Nicolaus. The company was maintained on Thursday, June 30 by Chardan Capital Markets. The stock has “Outperform” rating by Cowen & Co on Tuesday, September 8. Stifel Nicolaus maintained Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) rating on Wednesday, November 11. Stifel Nicolaus has “Buy” rating and $20 target. The firm has “Buy” rating given on Monday, December 12 by H.C. Wainwright. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Buy” rating by Cowen & Co on Wednesday, August 16.

Since December 18, 2017, it had 1 insider buy, and 0 selling transactions for $2.00 million activity. The insider Bain Capital Life Sciences Investors – LLC bought $2.00M.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The company has market cap of $452.38 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It currently has negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

Investors sentiment increased to 0.79 in 2017 Q3. Its up 0.24, from 0.55 in 2017Q2. It improved, as 9 investors sold Dicerna Pharmaceuticals, Inc. shares while 10 reduced holdings. 8 funds opened positions while 7 raised stakes. 10.37 million shares or 6.06% less from 11.04 million shares in 2017Q2 were reported. The Illinois-based Northern Corporation has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Dimensional Fund Advsrs L P reported 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Bridgeway, a Texas-based fund reported 168,300 shares. Fmr Limited Co has 1.47M shares. Barclays Public Limited Company stated it has 0% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). National Bank Of America De invested in 0% or 397 shares. The Massachusetts-based Geode Mngmt has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Moreover, Panagora Asset Management Inc has 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Ra Management Ltd Liability Co has 1.26% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 2.43M shares. Virtu Ltd Limited Liability Company, New York-based fund reported 19,861 shares. Eventide Asset Mgmt Ltd owns 377,000 shares for 0.12% of their portfolio. Birchview Cap L P holds 45,000 shares or 0.13% of its portfolio. Goldman Sachs reported 0% stake. Deutsche Savings Bank Ag invested 0% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). 436,665 are held by Vanguard Grp.

Investors sentiment increased to 1 in Q3 2017. Its up 0.16, from 0.84 in 2017Q2. It increased, as 22 investors sold OGE shares while 110 reduced holdings. 33 funds opened positions while 99 raised stakes. 123.28 million shares or 0.34% less from 123.70 million shares in 2017Q2 were reported. Raymond James Assoc reported 0.03% of its portfolio in OGE Energy Corp. (NYSE:OGE). 9,500 were reported by Moneta Group Incorporated Investment Advsrs Ltd Limited Liability Company. Farmers Merchants Invests reported 700 shares. Boothbay Fund Lc, New York-based fund reported 6,000 shares. 12,735 were accumulated by Raymond James Na. Zurcher Kantonalbank (Zurich Cantonalbank) holds 39,111 shares. Metropolitan Life Insur Communications Ny invested in 0.04% or 187,876 shares. State Street accumulated 7.56 million shares. 24,807 are owned by Stifel Fin Corporation. Cwm Limited Liability Corporation stated it has 2,200 shares or 0% of all its holdings. Minnesota-based Walleye Trading Limited Company has invested 0% in OGE Energy Corp. (NYSE:OGE). Tnb has invested 0.04% in OGE Energy Corp. (NYSE:OGE). Commerce Bancshares owns 28,004 shares for 0.01% of their portfolio. Ing Groep Nv accumulated 24,458 shares. Opus Mngmt accumulated 16,000 shares.

Alps Advisors Inc decreased Financial Select Sector Spdr F (XLF) stake by 26,528 shares to 650,375 valued at $16.82M in 2017Q3. It also reduced Newmont Mining Corp (NYSE:NEM) stake by 487,554 shares and now owns 222,427 shares. Randgold Resources Ltd (NASDAQ:GOLD) was reduced too.

Among 10 analysts covering OGE Energy (NYSE:OGE), 1 have Buy rating, 1 Sell and 8 Hold. Therefore 10% are positive. OGE Energy had 19 analyst reports since August 7, 2015 according to SRatingsIntel. As per Wednesday, September 27, the company rating was maintained by Jefferies. The rating was initiated by Bank of America on Tuesday, October 24 with “Sell”. Barclays Capital maintained the shares of OGE in report on Friday, March 18 with “Equal-Weight” rating. On Wednesday, October 18 the stock rating was maintained by KeyBanc Capital Markets with “Hold”. The stock has “Hold” rating by Wunderlich on Friday, November 6. The stock of OGE Energy Corp. (NYSE:OGE) earned “Hold” rating by Jefferies on Friday, August 4. The firm has “Hold” rating given on Monday, April 11 by Argus Research. Jefferies maintained the shares of OGE in report on Friday, July 21 with “Hold” rating. Goldman Sachs initiated the stock with “Hold” rating in Thursday, July 20 report. On Wednesday, December 27 the stock rating was downgraded by Edward Jones to “Hold”.

Since August 7, 2017, it had 0 insider purchases, and 2 insider sales for $214,418 activity. Forbes H Scott also sold $169,025 worth of OGE Energy Corp. (NYSE:OGE) on Monday, August 7. 1,250 OGE Energy Corp. (NYSE:OGE) shares with value of $45,393 were sold by CORBETT LUKE R.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *